SiBone (SIBN)
(Delayed Data from NSDQ)
$14.51 USD
+0.25 (1.75%)
Updated May 1, 2024 04:00 PM ET
After-Market: $14.50 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SIBN 14.51 +0.25(1.75%)
Will SIBN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SIBN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SIBN
Organon (OGN) Gears Up to Report Q1 Earnings: What's in Store?
What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?
SIBN: What are Zacks experts saying now?
Zacks Private Portfolio Services
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings
Other News for SIBN
SI-BONE To Present at BofA Securities 2024 Healthcare Conference on May 14, 2024
Piper Sandler Keeps Their Buy Rating on SI-Bone (SIBN)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: SI-Bone (SIBN), Conmed (CNMD) and Chemed (CHE)
Truist Financial Sticks to Their Buy Rating for SI-Bone (SIBN)
SI-BONE To Report First Quarter 2024 Financial Results on May 6, 2024